Percutaneous mesocaval shunt creation for portal thrombosis in a patient with a JAK2V617F mutation.
Thromb Res
; 234: 158-161, 2024 02.
Article
em En
| MEDLINE
| ID: mdl-38241766
ABSTRACT
Myeloproliferative neoplasms (MPN) are the most common cause of noncirrhotic, nontumoral portal vein thrombosis (PVT). Over 90 % of MPN patients with PVT carry the JAK2V617F mutation. Compared to other etiologies of PVT, patients with JAK2V617F MPNs are at increased risk of developing significant portal hypertension. However, when these patients develop refractory portal hypertensive complications requiring portosystemic shunt placement, they have limited options. Transjugular intrahepatic portosystemic shunt (TIPS) insertion is often not feasible, as these patients tend to have extensive, occlusive portal thrombus with cavernous transformation. Surgical portosystemic shunt creation can be an alternative; however, this is associated with significant mortality. In this report, we describe the novel use of a percutaneous mesocaval shunt for successful portomesenteric decompression in a patient with portal hypertension from PVT associated with JAK2V617F positive essential thrombocythemia.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Derivação Portossistêmica Transjugular Intra-Hepática
/
Trombose Venosa
/
Hipertensão Portal
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article